Smith, a microbiologist whose discovery revolutionize the field of genetic engineering, was a Johns Hopkins School of Medicine alumnus and professor emeritus ...
PCSK9 inhibition may be a suitable alternative for statin-intolerant patients, and recent data demonstrated its efficacy as ...
Major change for rare disease treatments on way, signals MHRA: United Kingdom Tuesday, November 4, 2025, 13:00 Hrs [IST] The rulebook for rare disease therapies will be overhauled ...
Boston-based Vertex reported revenue of $3.08 billion, an 11 percent gain from one year ago. That was ahead of analysts’ ...
Vertex Pharmaceuticals VRTX reported adjusted earnings of $4.80 per share for the third quarter of 2025, surpassing the Zacks ...
The Global Point-of-Care Molecular Diagnostics Market is projected to grow at a CAGR of 10.2% from 2026 to 2033, according to a new report published by Verified Market Reports®. The report reveals ...
Vertex Pharmaceuticals Inc. reported third-quarter sales that beat analysts’ expectations as the biotech company’s mainstay ...
People with prediabetes experience impaired insulin release and insulin resistance, explained Priya Jaisinghani, M.D., an ...
A promising “two-in-one” experimental drug could tackle both type 2 diabetes and heart disease by slashing cholesterol and ...
A new West Coast biotech has emerged into the busy in vivo cell therapy space, this time with the backing of Nobel Prize-winning CRISPR pioneer Jennifer Doudna, Ph.D. Azalea Therapeutics has bloomed ...
2hon MSN
Sugars on immune cells, not just blood vessel walls, may regulate the inflammatory disease process
New research has updated the understanding of how sugars, known as glycans, help immune cells move into the skin in the ...
While some practices remain controversial or speculative, biohackers are united by a shared curiosity: how can we engineer ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback